…cy, Summary of product characteristics, August 22, 2017. Free full text at www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004230/WC500234561.pdf No head-to-head trials have compared cladribine tablets with other disease-modifying therapies. To date, only one preliminary study from the MSBase group has examined this issue using a propensity score-matched analysis (Kalincik et al. ECTRIMS 2017; abstract P1138). The da…

…s diagnosed at a younger age (4.3/1000 PY if age 20-40 years at diagnosis) compared to an older age (11.5/1000 PY if older than 40 years). These results support previous reports of higher mortality rates in patients with MS. Back to top NfL examined as potential biomarker Numerous biomarkers have been proposed for predicting conversion from CIS: OCBs, kappa free-light chain, IgG against neurotropic viruses, chitinase-3-like protein-1, soluble CD27…